NCT06920212 is a NA clinical trial of FMT capsule in Fecal Microbiota Transplantation, sponsored by Shanghai 10th People's Hospital.

Who is sponsoring NCT06920212?

NCT06920212 is sponsored by Shanghai 10th People's Hospital.

What drugs are being tested in NCT06920212?

Interventions in NCT06920212: FMT capsule.

What condition does NCT06920212 study?

NCT06920212 studies Fecal Microbiota Transplantation.

Is NCT06920212 still recruiting?

NCT06920212 is currently active, enrolled. Last updated 9 April 2025.

Last reviewed 2025-04-09 · How we verify

NCT06920212

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Safety and Efficacy of Fecal Microbiota Transplantation (FMT) in the Treatment of Alzheimer's Disease

Active, enrolled NA Last updated 9 April 2025

What this trial tests

NA trial testing FMT capsule in Fecal Microbiota Transplantation in 30 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 October 2024

Primary endpoint
31 October 2025

31 December 2025

Quick facts

Lead sponsor	Shanghai 10th People's Hospital
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 October 2024
Primary completion	31 October 2025
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

FMT capsule

Conditions studied

Fecal Microbiota Transplantation — all drugs for Fecal Microbiota Transplantation →

Sponsor

Shanghai 10th People's Hospital

Who can join

Adults 50 to 85, any sex, with Fecal Microbiota Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the clinical safety and efficacy of FMT in AD patients, as well as the changes in the gut microbiota of AD patients before and after FMT.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Microbial SCFAs as epigenetic mediators: fine-tuning the gut-brain axis in neurodegenerative disorders.
Xu X, Cheng Y, Liu X, Ding W, et al · · 2026 · PMID 41798063 · DOI 10.1016/j.crmicr.2026.100574
The gut microbiota influences neurodegenerative diseases through the gut-brain axis: molecular mechanisms and effects on immune function.
Yang J, Song X, Yan S, Li Q, et al · · 2025 · PMID 41601624 · DOI 10.3389/fimmu.2025.1739329
Molecular links between inflammatory bowel disease and Alzheimer's disease through immune signaling and inflammatory pathways.
Durairajan SSK, Singh AK, Sulaiman SM, Patnaik S, et al · · 2025 · PMID 41480321 · DOI 10.3748/wjg.v31.i48.111301

Verify or expand the search:

Other trials of FMT capsule

Trials testing the same drug.

NCT07533227 — Intestinal Microbiota Transplantation for Treating Advanced Tumor Cachexia · Phase 2 · not yet recruiting
NCT07481422 — Safety and Efficacy of Lyophilized Faecal Microbiota Transplantation Via Capsules in Treatment of Irritable Bowel Syndro · Phase 1, PHASE2 · recruiting
NCT06649981 — Aging Resilience Through Microbiota Optimization and Regulation · Phase 1 · active not recruiting
NCT05427331 — FMT Capsules in Treatment of Patients With Insomnia Clinical Research · NA · unknown
NCT04130763 — Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of Anti- PD-1 · Phase 1 · completed

Other recruiting trials for Fecal Microbiota Transplantation

Currently open trials in the same condition.

NCT06282952 — Health Outcomes in C-Section Infants With Fecal Microbiota Transplantation · NA · recruiting
NCT07149441 — Efficacy and Mechanism of FMT in the Treatment of Inflammatory Bowel Disease: an Open-label Randomized Controlled Study · NA · active not recruiting
NCT05790356 — Fecal Microbial Transplantation for Rheumatoid Arthritis Trial · NA · recruiting
NCT06782880 — Fecal Microbiota Transplantation for the Prevention of Infectious Complications After Liver Transplantation · NA · recruiting
NCT05821010 — Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis · Phase 2 · recruiting

Other Shanghai 10th People's Hospital trials

Trials by the same sponsor.

NCT07528040 — An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With C · not yet recruiting
NCT07370441 — Amino Acid (15) Peritoneal Dialysis Solution for Nutritional Improvement in Peritoneal Dialysis Patients · Phase 4 · not yet recruiting
NCT07328100 — Efficacy and Safety of Coenzyme I for Injection on Vascular Aging. · NA · not yet recruiting
NCT06783296 — Efficacy and Safety of Renal Denervation on Isolated Diastolic Hypertension · NA · not yet recruiting
NCT07204496 — A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06920212 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai 10th People's Hospital
Last refreshed: 9 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06920212.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing